Bio-techne Corp.

Organisation

614 McKinley Place N.E., Minneapolis, MN, United States, 55413

Headquarters

3100

Employees

Health Technology

Industry

Charles Kummeth

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Price

Target

Bio-techne Corp. (TECH) Price vs Consensus Price Target

As per the chart shown above, analysts believe that the Bio-techne Corp. (TECH) share price will touch around $74.91 in next 12-months.

Currently 19 wall-street analysts regularly analyze the financials of Bio-techne Corp. on a frequent basis to provide recommendations along with target share price. 19 analysts offering 12-month price forecasts for Bio-techne Corp. (TECH) have a share price target of $74.91. This median of share price forecast represents a 42.44% upside from the latest price of $52.59 as on 02.04.26.

Bio-techne Corp. (TECH) Share Price Forecast

Home

US Stocks

Bio-techne Corp. (TECH)

Bio-techne Corp. Stock Forecast

Bio-techne Corp. Stock Forecast & Price Target (Analyst Recommendation) | INDmoney

Percentage Difference

Bio-techne Corp. (TECH): Difference between Current Price & Median Forecasted Price

Below is a chart showing the percentage difference between Bio-techne Corp.'s share price and its median forecast price. As on 02.04.26, the difference is -8.48%

Bio-techne Corp. Forecast and Target Price

Bio-techne Corp. (TECH) Share Price Forecast

Bio-techne Corp. (TECH) Price vs Consensus Price Target

Bio-techne Corp. (TECH) Share Price Forecast v/s Share Price Today

Bio-techne Corp. (TECH): Difference between Current Price & Median Forecasted Price

Bio-techne Corp. (TECH) Share Price Technical Analysis

50 Day Moving Average v/s Current Share Price

200 Day Moving Average v/s Current Share Price